2007 Final Program - Society of Behavioral Medicine

2007 SBM Annual Meeting & Scientific Sessions March 21-24, 2007 FINAL PROGRAM
Rapid Communications Posters Thursday, March 22, 2007 • 6:30 PM-8:00 PM • Poster Session B
hypothesized that the severity of the stressful event may lead to
cognitive and emotional processing, and that processing in turn
leads to growth - in short, that depth of processing would mediate
the relation between stressor severity and growth. Communitydwelling
women (n = 163) wrote essays about a stressful
event occurring in the previous three years and completed the
Posttraumatic Growth Inventory (PTGI). Essays were rated for
depth of cognitive and emotional processing. Event severity was
rated using the PERI Life Events Scale. Using multiple regression,
we found that stressor severity predicted growth (p = .04), as well as
depth of processing (p < .01). In turn, depth of processing predicted
growth (p < .01). As predicted, the effect of stressor severity on
growth was mediated by depth of processing. This finding sheds
light on the mechanisms by which stress-related growth occurs. This
has theoretical implications in terms of our understanding of coping
with stressors and stress-related growth. In addition, the applications
of this finding to clinical interventions in will be discussed.
CORRESPONDING AUTHOR: Aliza Z. Weinrib, MA,
Psychology, University of Iowa, Iowa City, IA, 52242; alizaweinrib@uiowa.edu
2487
WOMEN’S SEXUAL MOTIVATION AND SATISFACTION
AFTER CANCER
Sara I. McClelland, MA and Tracey A. Revenson, PhD
Psychology, The Graduate Center, CUNY, New York, NY.
Resuming sexual activity after diagnosis or treatment for cancer is a
complex phenomenon that is not well understood. In this analysis,
we use a model of female sexual dysfunction developed by Basson
(2000) in order to focus on two aspects of sexual activity that are
important for cancer survivors: motivations for sexual activity and
sexual satisfaction. The assessment of these aspects of sexuality is
more complex than simply assessing the frequency of intercourse or
ability to achieve orgasm.
In this study, we systematically reviewed 60 measures that have been
developed for use within medical, psychological, and clinical settings
to assess female sexual adaptation, activity, and function. The goal
of our analysis was to examine how researchers have assessed the
concepts of motivation and sexual satisfaction for women in general,
and with female cancer survivors in particular. The measures were
coded systematically at the item-level (1,367 items in total) by two
raters; inter-rater reliabilities were good (> .85).
The findings revealed three major themes: (1) only 5% (63) of
the items in scales were written expressly to assess the impact of
illness on a woman’s sexuality; (2) the small percentage of items
that did assess the impact of illness did not include assessments of
sexual satisfaction, despite the fact that satisfaction was a critical
component of sexuality within the full data set of 1,367 items; and
(3) motivation for sexual activity was most often assessed through
items that measured a woman’s sexual desire, although this concept
is still-ill defined and only one possible motivating factor for sexual
activity.
With these results, we argue that the concepts of sexual motivation
and sexual satisfaction need to be more fully theorized and
operationalized for research within cancer survivor populations
and need to be gender-specific. Without this work, clinicians and
researchers will continue to assess and advise women about sexual
function and sexual activity with limited information on how
women are experiencing their sexuality after cancer.
CORRESPONDING AUTHOR: Sara I. McClelland, MA,
Psychology, The Graduate Center, CUNY, New York, NY, 10016;
smcclelland@gc.cuny.edu
2488
HEALTH RELATED QUALITY OF LIFE FOR MEN WITH
LOCALIZED PROSTATE CANCER UNDERGOING PRIMARY
ANDROGEN DEPRIVATION THERAPY OR SURGERY
David Latini, PhD, 1 Natalia Sadetsky, MD, MPH, 2 Janet E. Cowan,
MA 2 and Peter R. Carroll, MD 2
1
Baylor College of Medicine, Houston, TX and 2 Urology, UCSF,
San Francisco, CA.
Purpose:
Androgen deprivation is used commonly to treat prostate cancer
either as primary, neoadjuvant or adjuvant therapy. However, little
is known about how primary ADT (PADT) affects health-related
quality of life (HRQOL). We evaluated changes in HRQOL in
men undergoing PADT, compared with men undergoing radical
prostatectomy (RP) as primary therapy.
Methods:
We collected HRQOL data using the SF-36 v. 1.0 and UCLA
Prostate Cancer Index. Data for 1,788 men enrolled in CaPSURE,
a national PCa registry, were analyzed to examine HRQOL changes
from pre-treatment to 24 months post-baseline. The groups (PADT
vs. RP) were compared on baseline sociodemographic and clinical
characteristics using the chi-square test and t-test. Changes in
HRQOL over time were examined using a mixed model approach,
adjusting for clinical risk, race, education, age, time of HRQOL
assessment and interaction between treatment type and time.
Results:
PADT patients presented with significantly higher Gleason scores,
higher PSA values, and more advanced clinical stage than men
undergoing RP (all p < .01). PADT patients were significantly older,
less educated, less likely to have private insurance and more likely
to be non-white (all p < .01). At 24 months, the largest declines for
PADT patients were in Sexual Bother (mean change: 22.5 points)
and Function (18.8), and Role-Physical (12.9). For RP men, the
largest declines at 24 months were in Sexual Function (26.6) and
Bother (23.0), and Urinary Function (15.7). There were significant
group by time differences in each HRQOL domain except Bodily
Pain.
Conclusion:
Men receiving PADT and RP monotherapy show very different
post-treatment HRQOL changes. PADT patients experience
more decrements in general HRQOL and fewer in disease-specific
HRQOL than RP patients. Both groups experience substantial
decrements in Sexual Function and Bother at 24 months. PADT
men report more gradual declines in both areas, but are less likely to
see recovery of Sexual Function at 24 months than RP men.
CORRESPONDING AUTHOR: David Latini, PhD, Baylor
College of Medicine, Houston, TX, 77030; latini@bcm.tmc.edu
~ 93 ~